ESSA Pharma Inc (EPIX) - Total Assets
Based on the latest financial reports, ESSA Pharma Inc (EPIX) holds total assets worth $110.50 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ESSA Pharma Inc (EPIX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ESSA Pharma Inc - Total Assets Trend (2012–2024)
This chart illustrates how ESSA Pharma Inc's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of ESSA Pharma Inc to evaluate the quality of earnings relative to operating cash generation.
ESSA Pharma Inc - Asset Composition Analysis
Current Asset Composition (September 2024)
ESSA Pharma Inc's total assets of $110.50 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.0% |
| Accounts Receivable | $162.97K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how ESSA Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ESSA Pharma Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ESSA Pharma Inc's current assets represent 99.6% of total assets in 2024, an increase from 68.7% in 2012.
- Cash Position: Cash and equivalents constituted 81.0% of total assets in 2024, up from 57.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 31.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
ESSA Pharma Inc Competitors by Total Assets
Key competitors of ESSA Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
ESSA Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 69.07 | 36.95 | 66.92 |
| Quick Ratio | 69.07 | 36.95 | 67.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $108.90 Million | $128.52 Million | $79.37 Million |
ESSA Pharma Inc - Advanced Valuation Insights
This section examines the relationship between ESSA Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.09 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -14.1% |
| Total Assets | $128.11 Million |
| Market Capitalization | $9.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values ESSA Pharma Inc's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ESSA Pharma Inc's assets decreased by 14.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ESSA Pharma Inc (2012–2024)
The table below shows the annual total assets of ESSA Pharma Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | $128.11 Million | -14.09% |
| 2023-09-30 | $149.12 Million | -12.02% |
| 2022-09-30 | $169.50 Million | -14.46% |
| 2021-09-30 | $198.17 Million | +145.94% |
| 2020-09-30 | $80.58 Million | +47.10% |
| 2019-09-30 | $54.77 Million | +241.97% |
| 2018-09-30 | $16.02 Million | +185.66% |
| 2017-09-30 | $5.61 Million | -46.10% |
| 2016-09-30 | $10.40 Million | +38.79% |
| 2015-09-30 | $7.49 Million | +78.37% |
| 2014-09-30 | $4.20 Million | +538.21% |
| 2013-09-30 | $658.38K | +45641.16% |
| 2012-09-30 | $1.44K | -- |
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.